Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

NCT02059642 is registered in ClinicalTrials.gov with Alcobra Ltd. as lead sponsor.

NCT NCT02059642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02059642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Lead sponsor
Alcobra Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2014
Completion date
September 30, 2014
Enrollment
300 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

adhd, attention-deficit/hyperactivity disorder, predominantly inattentive type